Hemolytic anemia after switching from infliximab originator to biosimilar CT‐P13 in a patient with inflammatory bowel disease: A case report

Strik, Anne S.; D’Haens, Geert R.; Löwenberg, Mark

doi:10.1002/ccr3.2394

Cited by 8 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Switchbacks to the previous formulation of IFX resulted both in maintaining effectiveness and the disappearance of side effects. The emergence of side effects after switching and their resolution after reverting to the formulation of IFX used previously may have been a result of the nocebo effect, 25 although at least a subset of emerging adverse effects, such as hemolytic anemia, 26 may also reflect incompletely understood immune-mediated mechanisms.…”

Section: Discussionmentioning

confidence: 99%

Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study

Hanžel

Jansen

Steege

et al. 2021

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background Though a single nonmedical switch from the originator infliximab (IFX) to a biosimilar is considered effective and safe for most patients with inflammatory bowel disease (IBD), very limited data are available on multiple successive switches. Methods We performed a prospective multicenter cohort study of adult IBD patients who underwent 2 switches from the originator IFX to CT-P13 to SB2 (group 1), 1 switch from CT-P13 to SB2 (group 2), and 1 switch from the originator IFX to CT-P13 (group 3). Patients were assessed at 4 and 12 months since the most recent switch for remission using clinical (physician’s assessment) and biochemical (C-reactive protein [CRP], and fecal calprotectin [FC]) measures. Patients discontinuing treatment for ineffectiveness or adverse events before month 12 were imputed as nonremitters. Results One hundred seventy-six patients (Crohn’s disease 71%, ulcerative colitis 27.8%, IBD unclassified 1.2%; group 1, 69; group 2, 80; group 3, 27) were included. At 12 months after the most recent switch 76.9% (40 of 52, group 1), 65.7% (46 of 70, group 2) and 76.9% (20 of 26, group 3) of patients were in clinical remission. Treatment persistence at 12 months was 85.0%, 87.0%, and 70.1%, respectively. There were no significant differences in the rate of clinical, CRP, FC remission, or treatment persistence at 12 months between the 3 groups. Infusion reactions occurred in 1.7% of patients (3/176), all in patients with antidrug antibodies from group 2. Conclusions Multiple successive switching and switching between biosimilars of IFX seemed to be effective and safe.

show abstract

Section: Discussionmentioning

confidence: 99%